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Protein cleavage is a common feature in human neurodegenerative disease. Ataxin-3 protein with an
expanded polyglutamine (polyQ) repeat causes spinocerebellar ataxia type-3 (SCA3), also called
Machado–Joseph disease, and is cleaved in mammalian cells, transgenic mice and SCA3 patient brain
tissue. However, the pathological signiﬁcance of Ataxin-3 cleavage has not been carefully examined. To
gain insight into the signiﬁcance of Ataxin-3 cleavage, we developed a Drosophila SL2 cell-based model
as well as transgenic ﬂy models. Our data indicate that Ataxin-3 protein cleavage is conserved in the ﬂy
and may be caspase-dependent as reported previously. Importantly, comparison of ﬂies expressing either
wild-type or caspase-site mutant proteins indicates that Ataxin-3 cleavage enhances neuronal loss in vivo.
This genetic in vivo conﬁrmation of the pathological role of Ataxin-3 cleavage indicates that therapies target-
ing Ataxin-3 cleavage might slow disease progression in SCA3 patients.
INTRODUCTION
Protein cleavage plays a critical role in a number of different
neurodegenerative disease situations. Cleavage of amyloid
precursor protein (APP) by a series of proteases leads to the
production of beta-amyloid (Ab) peptide and the relative
abundance of Ab 42 versus Ab 40 is thought to play an
important role in the development of Alzheimer’s disease
(1). Increasing evidence also indicates that caspase-mediated
cleavage of APP plays important roles in Ab production (2).
Tau protein, found in Alzheimer’s disease and other disease
lesions, is also subject to cleavage by caspases, which may
contribute to disease progression in Alzheimer’s disease and
tauopathies (3,4). Huntingtin protein, which is responsible
for Huntington’s disease (HD), is also cleaved by proteases
and its cleavage fragments are detected in HD patient brains
(5). Site-directed mutagenesis targeting a caspase recognition
site of the Huntingtin protein was shown to drastically
reduce HD-like neurodegeneration in mice (6).
HD is one of a larger class of diseases known as polygluta-
mine (polyQ) diseases, of which there are numerous ataxias,
including the most common dominantly inherited ataxia
spinocerebellar ataxia type-3 [SCA3, also known as
Machado–Joseph disease (MJD)]. Data from mouse trans-
genic models and human disease tissue indicate that the patho-
genic Ataxin-3 protein, encoded by the ATXN3 gene, is
proteolyzed in vivo (7). In mice, proteolysis is seen in trans-
genic lines with high protein expression levels that show
degeneration, and is stronger in animals that are sick, and
milder in those without symptoms. A normal protein cleavage
product is reported, although it is unclear whether protein
expression levels are comparable with that of disease
animals. Epitope mapping of the cleavage site indicated that
it occurs N-terminal to aa221, more recently narrowed to N-
terminal to aa190, and the resulting cleavage fragment
includes the polyQ repeat (7,8). A similar proteolytic fragment
was seen in western samples from three human patients (7).
These studies suggest that proteolysis of the pathogenic
protein may occur, may contribute to disease, and that the
stable fragment contains the pathogenic polyQ repeat.
In a second study, proteolysis of the normal and pathogenic
Ataxin-3 proteins was seen in Cos-7 cells upon
staurosporine-induced apoptosis (9). Endogenous Ataxin-3
with a normal polyQ length repeat also underwent cleavage
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was inhibited by caspase inhibitor zVAD-fmk. The cleavage
was mapped to a similar location as in the Goti et al. (7)
study, and was shown to be largely caspase-1 dependent.
Examination of patient brain tissue for proteolytic fragments
failed to reveal a clear fragment.
DrosophilamodelsexpressinghumanAtaxin-3proteinshave
provided novel insights into SCA3 disease (10–13). The
Ataxin-3 protein has an N-terminal ubiquitin protease domain,
with the polyQ repeat near the C-terminal region of the
protein (14). The ubiquitin protease domain has been shown to
havede-ubiquitinationactivity,andisspeculatedtobeaubiqui-
tin chain editing enzyme (15,16). In the ﬂy, the activity of the
normal protein associated with the ubiquitin protease domain
substantially mitigates toxicity of the pathogenic protein (13).
When this domain is deleted (as with an N-terminally truncated
protein),oriftheubiquitinproteasedomainismutatedtomakeit
inactive (C14A mutation), the protein with a pathogenic repeat
issubstantiallymoretoxicinbothdegreeandtissuerangeoftox-
icity.ThesedataindicatethattheN-terminaldomainhasactivity
to mitigate toxicity of the pathogenic protein, and that, should
N-terminal proteolysis occur, it is predicted to substantially
enhance toxicity of the protein. N-terminal truncation of the
protein also affects the ability of the protein to interact with
P97/VCP, which also enhances toxicity (17).
Previous reports about Ataxin-3 protein cleavage are in cell-
based studies or correlative studies in transgenic mouse
models or patient brain samples (7,9,18,19). In order to gain
experimental evidence of the pathological signiﬁcance of
Ataxin-3 protein cleavage in vivo, we used the fruit ﬂy
model system to deﬁne potential cleavage of the Ataxin-3
protein in the nervous system in vivo, and the consequences
of preventing that cleavage pattern. Our data suggest that
Ataxin-3 cleavage enhances the progression of neurodegenera-
tion in the ﬂy model for SCA3, indicating that such cleavage
in the human situation may enhance disease progression.
RESULTS
Ataxin-3 protein is cleaved in Drosophila in a pattern
similar to mammals
Studies using various antibodies suggest that the major clea-
vage product of Ataxin-3 includes the polyQ domain, and
that expanded pathogenic Ataxin-3 protein from the brain
tissues of transgenic mouse models or SCA3 patients gener-
ates a 36 kDa fragment, with the size fragment dependent
on the length of the polyQ repeat (7,9). We examined
whether similar protein cleavage products were generated in
the nervous system of Drosophila expressing Ataxin-3 with
either normal length (Atx3Q27) or expanded polyQ domain
(Atx3Q84). Polyclonal antibody to Ataxin-3 and the mono-
clonal antibody 1H9, which recognizes aa221–224, as well
as anti-Myc and anti-Flag antibodies, were chosen to
compare our data with previous studies (Fig. 1A) (7,9,18). Pre-
viously reported Myc-tagged Ataxin-3 proteins of normal or
expanded polyQ length were used along with newly generated
double-tagged (N-terminal Myc and C-terminal Flag) proteins.
Analysis of the cleavage patterns of the normal and patho-
genic protein with these different antibodies revealed that
the Ataxin-3 protein is cleaved in the nervous system in vivo
to generate smaller stable fragments that include the polyQ
repeat (Fig. 1B). With the 1H9 and anti-MJD antibodies, sig-
niﬁcant amounts of cleavage products were readily detected.
The pathogenic Atx3Q84 protein runs at 73 kDa, and is
cleaved to generate fragments running at 37 kDa. Depend-
ing on the antibody, the cleavage product appears as a
doublet or single band. The normal length Atx3Q27 protein
generates a smaller fragment of 22 kDa, suggesting that
the major cleavage product includes the polyQ domain
(Fig. 1B). The presence of 37 kDa fragments, similar in
size to the fragment seen in mouse and human (7), with
expression of pathogenic Ataxin-3 suggests that Ataxin-3 clea-
vage is conserved in Drosophila. Interestingly, our initial
studies showed that cleavage of Ataxin-3 was much more pro-
minent when the protein was expressed in the nervous system
than in the eye, which has predominantly accessory cells along
with neuronal cells (Supplementary Material, Fig. S1). The
full-length Ataxin-3 protein is also not very toxic to non-
neural cells of the eye (1), suggesting that the cleavage of
the protein may be more particular in vivo to the nervous
system, and that this may relate to the toxicity of the protein.
The anti-Myc antibody which recognizes the N-terminal
end of tagged forms of Ataxin-3 protein highlighted the full-
length protein, which migrated just below the 75 kDa
marker, and no signiﬁcant smaller products (Fig. 1B). This
indicated that cleavage products do not include the N-terminal
end of the protein. With the double-tagged protein, we
observed a similar cleavage pattern of the Atx3Q84 protein
indicating C-terminal cleavage. Notably, antibodies to the
C-terminal FLAG tag detect a cleavage product migrating
just above 37 kDa, further conﬁrming that stable cleavage
products are derived from the C-terminus of the protein
(Fig. 1C).
Caspase inhibitor zVAD-fmk inhibits Ataxin-3 protein
cleavage in S2 cells
Previous reports suggest that Ataxin-3 protein cleavage is
dependent on caspase activities and is blocked by caspase
inhibitors (9,19). Calpain proteases and the proteasome have
also been implicated in studies in vitro using neuroblastoma
cell extracts (18). To further deﬁne potential proteases that
may function for protein cleavage in the ﬂy, we developed a
Drosophila SL2 cell-based system to determine whether the
Ataxin-3 protein is proteolyzed by any of the proteases pre-
viously implicated using various chemical inhibitors (Fig. 2A).
As observed in the ﬂy in vivo, we detected the 37 kDa
cleavage products when the pathogenic Atx3Q84 protein
was transiently expressed in SL2 cells (Fig. 2B). The cleavage
pattern of the protein in SL2 cells was similar to the cleavage
pattern of the protein in the ﬂy in vivo (Supplementary
Material, Fig. S2). Additional cleavage products were also
detected in cultured cells, most prominently a fragment of
50 KDa (  in Fig. 2B,    in Supplementary Material,
Fig. S3). We then used inhibitors to deﬁne potential cleaving
proteases. zVAD-fmk, a broad caspase inhibitor, consistently
reduced the level of 37 kDa fragment, while the control
peptide zFA-fmk had no effect (Fig. 2B, Supplementary
Material, Figs S3 and S4). Interestingly, with zVAD-fmk,
4844 Human Molecular Genetics, 2009, Vol. 18, No. 24there appeared to be an accumulation of a higher molecular
weight fragment (  in Supplementary Material, Fig. S3),
suggesting the possibility of sequential processing of the
Ataxin-3 protein.
Although the proteasome inhibitor MG-132 and the calpain
inhibitor ALLN have been previously shown to inhibit
Ataxin-3 cleavage in vitro (18), in SL2 cells, only MG-132
inhibited the appearance of a minor band (    in Supplemen-
tary Material, Fig. S3), but it did not inhibit generation of
the 37 kDa fragments. Furthermore, when zVAD-fmk and
MG-132 were combined, the results were additive rather
than synergistic, suggesting that the proteasome and caspases
may act independently.
Site-directed mutagenesis of caspase-recognition sites
signiﬁcantly modify Ataxin-3 protein cleavage
in cells and in the ﬂy
Goti et al. (7) used a series of monoclonal antibodies to ident-
ify the potential Ataxin-3 protein cleavage site. Those studies
indicated that the cleavage site may be near or just anterior to
the ubiquitin-interacting motifs (UIMs) N-terminal to the
polyQ repeat. Berke et al. (9) reported several putative
caspase-recognition sites and showed that the modiﬁcation
of six or nine caspase sites by site-directed mutagenesis elimi-
nated the appearance of cleavage products in Cos-7 cells. The
data with zVAD-fmk indicated that Ataxin-3 is a target of
Figure 1. Ataxin-3 protein cleavage products are generated in Drosophila.( A) Schematic representation of Ataxin-3 proteins used. Site of the epitopes for the
antibodies used are also indicated. (B) and (C) Western immunoblot analysis of proteins expressed in the brain of 7d ﬂy heads. (B) Initial studies performed with
Myc-Atx3Q27 and Myc-Atx3Q84 proteins. Left, Anti-Myc antibody detects the full-length proteins. Middle, the mouse monoclonal antibody 1H9 and right, the
polyclonal anti-MJD antibody detect Ataxin-3 fragments migrating at 22 kDa for Atx3Q27 and 37 kDa for Atx3Q84. Each antibody also detects non-speciﬁc
bands when compared with the control. Strong signals are detected as SDS-insoluble fractions in the stacking gel. (C) Left, transgenic Drosophila head extracts
expressing Myc-Atx3Q84-Flag show a similar cleavage pattern by 1H9, of the full-length protein and 37 kDa fragments. Right, anti-Flag antibody detects the
full-length protein and a 37 kDa fragment. These data suggest that 37 kDa fragments, also reported in transgenic mouse and some MJD patient samples, are
likely to contain the C-terminal portion of MJD protein, as well as the polyQ domain of the protein. Genotypes: (B) elav-gal4/þ; UAS-Myc-Atx3Q27/þ or
UAS-Myc-Atx3Q84/þ and (C) elav-gal4/þ; UAS-Myc-Atx3Q84-Flag/þ. Full-length proteins, ,Q84 or ,Q27, fragments indicated as  Q27f and  Q84f.
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caspase cleavage, we modiﬁed the aspartic acid residues to
asparagines at select caspase sites. Because of our interest in
the 37 kDa fragments, we focused on the six putative
caspase sites at amino acids 171, 208, 217, 223, 225 and
228 (Fig. 3A).
Upon generation of the caspase-resistant forms, we found
that caspase cleavage of Ataxin-3 is a dynamic process.
That is, single site (D208N or D217N) or even triple mutation
(D171/208/217N) of the putative caspase sites did not fully
eliminate cleavage, but rather lead to an alteration in the clea-
vage pattern in SL2 cells (Supplementary Material, Fig. S5
and data not shown). Strikingly, however, elimination of all
six putative caspase-sites (6M) eliminated the 37 kDa frag-
ments in SL2 cells (Supplementary Material, Fig. S5A). Such
mutation of the protein also had an effect on the overall
mobility of the protein in gels. This may be due to a confor-
mational change caused by the mutations or could result from
additional cleavage at the C-terminal end of the protein
(9,19).
To extend these ﬁndings in vivo in order to understand the
pathological impact of modiﬁed Ataxin-3 protein cleavage,
we generated transgenic animals expressing either wild-type
protein (Myc-Atx3Q84-Flag (WT)) or the sextuplet mutant
protein (Myc-Atx3Q83-Flag (6M)). Analysis of ﬂies expres-
sing equal levels of these proteins revealed that the 6M
mutant protein had dramatically reduced levels of cleavage
product in vivo (Fig. 3). Whereas the Myc-Atx3-Q84 protein
showed two cleavage products at the 37 kDa region (  U
and   D in Fig. 3B), the upper fragment of the double-tagged
Myc-SCA3Q84-Flag protein was typically more prominent;
thus, the C-terminal Flag tag may inﬂuence the Ataxin-3
protein cleavage process. The 6M mutant protein, however,
which also contained the C-terminal Flag tag, completely
lacked the upper 37 kDa band, and only faint signals were
detected for the lower molecular weight fragment.
The amount of SDS-insoluble material in the stacking gel in
the 6M caspase-mutant form of the protein was also signiﬁ-
cantly reduced, as detected by the anti-MJD antibody
(Fig. 3B). Interestingly, the amount of SDS-insoluble material
trapped in the stacking gel appeared to correlate with the
amount of the upper 37 kDa product (  U). In the 6M trans-
genic lines, lines with the lowest amount of cleavage product
also showed the lowest amount of SDS-insoluble material with
the anti-MJD antibody (data not shown).
Sextuplet caspase-site mutation (6M) does not signiﬁcantly
modify nuclear inclusion formation
The correlation between the amount of SDS-insoluble material
by western analysis and the amount of the upper 37 kDa
fragment raised the interesting hypothesis that this fragment
may act as a seed for the formation of nuclear inclusions in
tissues expressing the pathogenic Ataxin-3 protein. To test
this hypothesis, we conducted a time course experiment to
determine whether there was a difference in onset or size of
nuclear inclusion formation by Ataxin-3 in vivo. We used
the late-onset rhodopsin (rh1-Gal4) driver that allows sensi-
tive analysis of inclusion formation (11,13).
These studies revealed no difference in protein accumu-
lation between the WT and 6M form of pathogenic Ataxin-3
with 7d animals, showing a similar level and size of nuclear
inclusions between WT and 6M ﬂies (Fig. 4). Analysis at
earlier time points also indicated that the rate of inclusion
Figure 2. zVAD, a broad-acting caspase inhibitor, can suppress Ataxin-3 protein cleavage in an SL2-cell-based system. (A) Experimental procedure to detect the
effect of various protease inhibitors on Ataxin-3 protein cleavage in SL2 cells. Expression of the Ataxin-3 protein was driven by heat shock using a Gal4
(pHS-gal4) construct. The construct in all cases was pUAST-Myc-Atx3Q84. Drug was added 1 h prior to the ﬁrst heat shock and was then continuously
present until harvesting of the cells. (B) Ataxin-3 protein cleavage pattern in SL2 cells. The full-length protein is marked with a carrot (,) and the
37 kDa fragments highlighted with an arrow. In addition to the 37 kDa fragments seen in the ﬂy in vivo, additional Ataxin-3 fragments were detected in
SL2 cells, most prominently a fragments at 50 kDa ( ). zVAD, a general caspase inhibitor, inhibited the production of the 37 kDa fragments, without sig-
niﬁcantly altering the generation of the 50 kDa fragment. zFA, a control peptide, had no effect. All drugs were dissolved in DMSO, with ﬁnal percentage of
DMSO indicated.
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shown). Therefore, mutation of the caspase cleavage sites
and reduced proteolysis of the pathogenic Ataxin-3 protein
does not affect protein accumulation. This ﬁnding also
suggests that protein misfolding and clearance are not signiﬁ-
cantly affected by the presence of these caspase cleavage pro-
ducts, in agreement with MG-132 data from SL2 cells (see
Supplementary Material, Fig. S3).
Figure 3. Mutation of putative caspase recognition sites in Ataxin-3 dramatically reduces the amount of cleavage product in vivo.( A) Schematic diagram of
Atx3Q83 protein with the positions noted of the six caspase sites targeted in the site-directed mutagenesis (D-.N). (B) Western immunoblots. Top panel,
Ataxin-3 protein cleavage pattern probed with anti-MJD polyclonal antibody. Head extracts from 7d adult ﬂies were used. Sextuplet mutation strongly suppresses
Ataxin-3 protein cleavage. A non-speciﬁc band ( , 70 kDa) masks the full-length band. SDS-insoluble fractions are within the stacking gel, and the 37 kDa
cleavage products (  U and   D) are marked. Genotypes: elav-gal4/UAS-Myc-Atx3Q84, elav-gal4/ UAS-Myc-Atx3Q84-Flag (WT) and elav-gal4/
UAS-Myc-Atx3Q83-Flag (6M). Two transgenic lines of each genotype are shown. Lower panels are the same blot, probed with Anti-Myc for the full-length
protein, and with Anti-tubulin, for a loading control.
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neurodegeneration
We next asked whether reduction in caspase cleavage modu-
lates Ataxin-3 protein toxicity. Transgenic lines expressing
the same level of the WT or 6M proteins were expressed in
the nervous system with elav-gal4, and photoreceptor degener-
ation was assessed. Animals at 1d showed a mild degeneration
that was similar with expression of either the WT or 6M
protein, with 6–7 photoreceptor neurons per unit eye ommati-
dial cluster (Fig. 5). Flies expressing the WT pathogenic
protein, however, then underwent rapid neural loss, such that
15d animals retained only 3.1+0.34 photoreceptor neurons
per ommatidial cluster. In contrast, 15d ﬂies expressing the
6M caspase mutant protein had strikingly less degeneration,
with 5.19+0.17 PR neurons per ommatidial unit remaining.
To conﬁrm that the 6M mutant protein was properly folded
despite the caspase site mutations, we tested whether the
ability to suppress the pathogenicity of the truncated
SCA3Q78 protein was retained. Normally, the pathogenic full-
length Ataxin-3 protein, when co-expressed with the truncated
Q78 protein, has activity to suppress toxicity (Fig. 5C; 13).
These studies showed that the 6M protein retained suppressor
activity comparable with that of the protein without caspase
site mutations; this indicates that the 6M protein retains
normal Ataxin-3 activity and thus is likely properly folded.
Taken together, these data indicate that blocking caspase
cleavage of the Ataxin-3 protein dramatically mitigates
neural toxicity, despite the fact that nuclear inclusion for-
mation is unaffected.
DISCUSSION
Here we show that the Ataxin-3 protein undergoes cleavage in
SL2 cells and in the ﬂy in vivo. Cleavage of the protein has
been suggested to be important in the disease process (7).
We also show that mutation of six caspase sites in the
protein, which prevents cleavage of the protein in vivo, dra-
matically mitigates neural degeneration. These studies
provide in vivo evidence that cleavage of the Ataxin-3
protein in the nervous system may occur and may contribute
to disease progression.
Ataxin-3 protein cleavage is conserved
Ataxin-3 protein cleavage appears to be conserved as we
observed cleavage products from Drosophila SL2 cells and
the ﬂy nervous system similar to those reported from Cos-7
cells, transgenic mice and SCA3 patient brain tissue (7,9).
Western blot analysis, using polyclonal antibodies and the
1H9 antibody, indicates that the major cleavage product
from transgenic ﬂies contains the polyQ domain, because the
size of cleavage fragment varied depending upon the polyQ
length. Moreover, the 37 kDa fragments were greatly
reduced upon zVAD-fmk treatment that inhibits caspase
activity, similar to the ﬁndings in Cos-7 cells (9). Overall
conservation of the Ataxin-3 cleavage pattern suggests that
Drosophila can be used as a model to study the mechanism
and signiﬁcance of the protein cleavage.
One hypothesis we had initially was that Ataxin-3 cleavage
fragments may act as seeds or facilitators of protein aggrega-
tion. According to that hypothesis, we expected to see a delay
in nuclear inclusion formation or reduced inclusions in ﬂies
expressing the 6M mutant protein. However, there was no
obvious difference in inclusion onset, size or accumulation.
Pozzi et al. (19) identiﬁed multiple Ataxin-3 protein cleavage
products in Cos-7 cells and concluded that polyQ expansion in
the Ataxin-3 protein partially inhibited its proteolysis.
Additionally, it was suggested that the reduced proteolytic
degradation may enhance accumulation of full-length
Ataxin-3 protein, and thereby contribute to disease. Our data
showed no obvious difference in the dynamics of protein
accumulation with or without Ataxin-3 cleavage, and
suggested that the ubiquitin proteasome system is not differen-
tially affected by caspase site mutations. Despite this, we did
see a signiﬁcant reduction in the rate of photoreceptor neural
Figure 4. Elimination of putative caspase cleavage sites in Ataxin-3 protein
has little impact on protein accumulations. Cryosections immunostained for
Ataxin-3 protein with Myc (green, left panels) and for nuclei with Hoechst
(blue, right panels) of retinal sections from 7d adult ﬂies. Protein was
expressed with an adult onset driver (rh1-gal4), which is a sensitive method
to detect subtle differences in nuclear inclusion formation. Flies expressing
either the WT protein (top) or the 6M protein (bottom) showed inclusions
typical of the full-length Ataxin-3 protein, being of irregular shape when
assayed with this late-onset driver, and had the same onset and size. Higher
magniﬁcation insets are also included in the Myc panels. Genotypes:
rh1-gal4/ UAS-Myc-Atx3Q84-Flag (WT) and rh1-gal4/ UAS-Myc-Atx3Q83-
Flag (6M).
4848 Human Molecular Genetics, 2009, Vol. 18, No. 24Figure 5. Suppression of Ataxin-3 protein cleavage slows down the progression of photoreceptor neuronal degeneration. (A) Images of the retina by pseudopupil
technique,showing1dand15drepresentativeimagesofﬂiesexpressingMyc-Atx3Q84-Flag(WT)andMyc-Atx3Q83-Flag(6M).(B)Quantitationofthenumberof
photoreceptor neurons in 1d WT (green) and 6M (red) ﬂies. At 1d, ﬂies of both genotypes showed a similar degree of mild photoreceptor neuron degeneration.
Average number of photoreceptor neurons indicated +SD. 15d adult animals show greater degeneration in ﬂies expressing the WT protein than the 6M protein.
Genotypes: WT, elav-gal4/þ; UAS-Myc-Atx3Q84-Flag (WT)/þ and 6M, elav-gal4/þ; pUAS-Myc-Atx3Q83-Flag (6M)/þ.( C) The 6M protein retains normal
Ataxin-3 activity to suppress pathogenicity of the truncated Q78 protein. External eye pictures. Flies expressing the truncated Q78 protein alone (—) have a degen-
erate eye. The normal non-pathogenic Ataxin-3 protein [WT(Q27)] suppresses this toxicity when co-expressed; this suppression reﬂects the normal functional
activity of the Ataxin-3 protein (13). The pathogenic protein (WT) also shows suppressor activity, although not as striking as the non-pathogenic protein. The
6M protein (6M) has suppressor activity similar to the WT pathogenic protein. This indicates that the 6M protein is likely properly folded because it retains
normal activity of the Ataxin-3 protein to suppress polyQ toxicity. Genotypes: gmr-gal4 UAS-SCA3trQ78(S)/þ. gmr-gal4 UAS-SCA3trQ78(S)/
UAS-Myc-Atx3Q27-Flag[WT(Q27)].gmr-gal4UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q84-Flag(WT).gmr-gal4UAS-SCA3trQ78(S)/UAS-Myc-Atx3Q83-Flag(6M).
Human Molecular Genetics, 2009, Vol. 18, No. 24 4849degeneration when Ataxin-3 protein cleavage was inhibited by
mutation.
The UIM domains have been found to modulate toxicity of
the pathogenic Ataxin-3 protein (13). Because the 6M
mutations potentially affect residues in the ﬁrst UIM
domain, it is possible that the resulting changes in UIM func-
tion may change the overall toxicity. However, loss of UIM
function has been shown to increase, rather than decrease,
Ataxin-3 toxicity as observed here. We also used an assay in
vivo, the ability to suppress polyQ toxicity, to assess
Ataxin-3 function of the 6M mutant protein (13). This
showed that the 6M protein retains normal Ataxin-3 activity.
Thus, we suggest that the 6M mutant protein shows reduced
toxicity as a result of reduced protein cleavage. Overall,
these observations indicate that the cleavage product per se
may contribute to disease progression.
Protein cleavage and neurodegeneration
Cleavage of the protein may enhance neurodegeneration
in vivo in multiple ways. Cleavage fragments containing the
polyQ domain may interact with other proteins in a more
robust manner. Nuclear inclusions in polyQ diseases may
have components with differing exchange rates (20), and the
presence of short cleavage products may be more potent in
sequestering key cellular factors (21). Proteomic studies may
help reveal insight into why the WT protein is more toxic
than the 6M protein.
Cong et al. (22) made an interesting observation that the
short N-terminal fragment of Huntingtin with the expanded
polyQ remained predominantly monomeric in cells. Consid-
ering the apparent lack of a gross difference in the formation
of nuclear inclusions by Ataxin-3 cleavage in ﬂy neurons, it
is possible that 37 kDa cleavage products may not be
readily recruited into macroscopic inclusions, but rather
may exert toxic effects as soluble monomers. The apparent
increase in the SDS-insoluble aggregates with normal
Ataxin-3 protein cleavage, however, also suggests that the
cleavage product may be a part of the nuclear inclusions
in vivo. Moreover, the apparent decrease in the SDS-
insoluble aggregates with cleavage-site mutant protein
suggests that cleavage products may alter or trigger
changes in the biochemical properties of Ataxin-3 accumu-
lations. One such candidate process is cross linking by trans-
glutaminase. A recent study using chemical inhibitors of
transglutaminase showed mitigated SCA3-like disease
effects when fed to Drosophila (23). While the mechanism
of transglutaminase activation in the nervous system
remains to be fully elucidated, Ataxin-3 cleavage fragment
might selectively interact with transglutaminase and trigger
cross linking of aggregates (24).
Ataxin-3 has a ubiquitin chain-modifying activity, and
especially targets Lys63 linkages in mixed linkage ubiquitin
chains (16). Lys63-linked ubiquitin chains are thought to
play critical roles in the NF-kB signal transduction pathway
as well as in DNA repair. While the cellular targets are
unknown, it is possible that cleavage of the N-terminal ubiqui-
tin protease domain may compromise key cellular pathways
normally regulated by Ataxin-3. Moreover, because the clea-
vage product is likely to keep the UIM domain (19), it is an
interesting possibility that it may act as a dominant-negative
protein in the affected pathway.
Proteases involved in cleavage of Ataxin-3
Our data indicate that caspases may be responsible for
Ataxin-3 cleavage. Activation of caspases as diseased cells
undergo apoptosis pathways may trigger cleavage, as is the
case with endogenous Ataxin-3 protein in Cos-7 cells (9).
While it is reasonable to hypothesize that expanded Ataxin-3
protein may activate caspases that proteolyze Ataxin-3, the
observation that normal Ataxin-3, which does not cause neuro-
degeneration, is also cleaved, suggests that cleavage is not
necessarily a consequence of apoptosis. Caspases have been
known to play important roles in cell proliferation and
differentiation, beyond their roles as inducers/executioners of
apoptosis.
In SL2 cells, there were additional fragments beyond the
37 kDa fragment seen in mammalian models or ﬂy brain,
suggesting that Ataxin-3 protein cleavage may be a multi-
step process like for Huntingtin (25). The 37 kDa frag-
ments may have the longest half-life and thereby accumu-
late in vivo. Furthermore, z-VAD-fmk treatment
eliminated the 37 kDa fragment selectively in SL2 cell,
leaving the 50 kDa fragments unaffected. Haacke et al.
(18) suggested potential involvement of calpain proteases,
but calpain inhibitor ALLN had no effect in Ataxin-3 clea-
vage in SL2 cells. The apparent discrepancy could be due to
the use of different cell lines or culture conditions. MG-132
is widely used as an inhibitor of proteasome function and it
was effective in reducing Ataxin-3 protein cleavage in vitro
(18). We also observed that MG-132 treatment consistently
reduced the appearance of some cleavage products in SL2
cells, but the 37 KDa fragments were not affected.
When cells were treated with a combination of
zVAD-fmk and MG-132, we observed an additive but not
synergistic effect. These data suggest that Ataxin-3
protein cleavage is a complex process, involving multiple
cellular pathways.
In an attempt to deﬁne a speciﬁc caspase responsible for the
cleavage of the Ataxin-3 protein in vivo, we utilized dsRNA-
mediated RNA knockdown in SL2 cells and in the ﬂy. We
effectively decreased the levels of Dronc, Strica and Drice
in SL2 cells, but this had no effect on the Ataxin-3 cleavage
pattern (J. Jung and N. Bonini, unpublished data). We
further examined knockdown of caspase genes in the ﬂy
in vivo using P35 or dsRNA transgenic lines, but no consistent
effect was seen (J. Jung et al., unpublished data). It may be
necessary to knock down multiple caspases at once, or
knock down the genes to a greater extent than was achieved.
Our data demonstrate that Ataxin-3 protein is cleaved in
Drosophila as reported in mammalian model systems and in
SCA3 patients. Additionally, we provide experimental evi-
dence that Ataxin-3 cleavage signiﬁcantly enhances neural
degeneration induced by the pathogenic Ataxin-3 protein.
Taken together, these data indicate that suppression of
Ataxin-3 protein cleavage may signiﬁcantly slow down the
progression of neurodegeneration caused by expanded
Ataxin-3 protein expression.
4850 Human Molecular Genetics, 2009, Vol. 18, No. 24MATERIALS AND METHODS
Drosophila lines
Fly lines used were elav-gal4 (C155) for neural and brain
expression, rh1-gal4 for photoreceptor cell-speciﬁc
expression, and gmr-gal4 for eye expression. The Myc-tagged
Ataxin-3 lines have been described (13). Constructs with Flag
tags were generated by PCR and sequenced to conﬁrm integ-
rity. The WT double-tagged protein had a polyQ length of
Q84. The putative caspase site mutant constructs were gener-
ated by site-directed mutagenesis (Cat No 12397-014, Invitro-
gen). Several transgenic lines were chosen and used for
analysis. The polyQ length of the 6M mutant line was Q83.
Typically, lines Myc-Atx3Q84-Flag (WT) line #7 and
Myc-Atx3Q83-Flag (6M) line #1.1 were chosen for more
detailed analysis based on western immunoblot analysis of
similar protein expression with anti-Myc antibody. We also
analyzed additional lines with similar results, including lines
(WT) line #2 and (6M) line #3.1.
Immunoblots and immunohistochemistry
Western immunoblot analysis was performed as described
(26). Antibodies used were as follows. Rabbit anti-MJD
polyclonal antibody (gift of R. Pittman) (27), at 1:20 000, pre-
adsorbed overnight at 48C at 1:50 against 20–50 paraformal-
dehyde ﬁxed, dissected larvae. Mouse monoclonal antibody
1H9 at 1:1000 (ab78546, Abcam). Anti-Flag antibody
(F3165, Sigma, Company) at 1:1000. Mouse anti-Myc anti-
body (9E11, Santa Cruz Biotechnology) at 1:250. Mouse
monoclonal anti-tubulin at 1:1000 (Developmental Studies
Hybridoma Bank) was used as a loading control. Immuno-
staining of cryosections was performed as described pre-
viously (12), using the mouse anti-Myc antibody at 1:100.
When appropriate, blots were stripped with ReblotTM (Cat
No 2060, Millipore).
Cell culture studies
The pUAST-Myc-Atx3Q84-Flag expression vector (2 mg) was
co-transfected with the pHS-gal4 driver construct (1 mg) into
SL2 cells using the Effectene reagent (Cat No 11668027, Invi-
trogen) following the manufacturer’s protocol. Transfected
cells were incubated for 2 days at 258C. Cells were then
rinsed with PBS and fed fresh Schneider’s Drosophila
medium (Cat No 11720-034, Invitrogen) followed by a
30 min heat-shock treatment at 378C to induce Atx3Q84
protein expression. Heat-shocked cells were cooled at 258C
for 30 min and the heat-shock treatment was repeated. This
double heat-shock treatment was repeated twice more, with
a 24 h interval in-between. Cells were harvested for analysis
after 2 additional days of incubation at 258C. For drug treat-
ments, respective drug compounds were solubilized in
DMSO, and then diluted to indicated concentrations in the
normal growth medium. One hour prior to the ﬁrst heat-shock
treatment, cells were rinsed once with PBS and fed drug-
containing medium, followed by the standard heat-shock treat-
ment. Drugs used were N-benzyloxycarbonyl-val-ala-asp
(O-Me) ﬂuoromethyl ketone (zVAD-fmk, Sigma), benzyloxi-
carbonyl-L-phenylalanyl-ala-ﬂuoromethylketone (Z-FA.FMK,
Sigma), Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132,
EMD Biosciences) and N-acetyl-Leu-Leu-Nle-CHO (ALLN,
Cat No 208719, Calbiochem). Cells were kept in drug-
containing medium until harvest.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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